• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antiplatelet drugs block platelet activation by VITT patient serum.

作者信息

Smith Christopher W, Montague Samantha J, Kardeby Caroline, Di Ying, Lowe Gillian C, Lester William A, Watson Steve P, Nicolson Phillip L R

机构信息

Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; and.

Haemophilia Comprehensive Care Centre, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

出版信息

Blood. 2021 Dec 23;138(25):2733-2740. doi: 10.1182/blood.2021012277.

DOI:10.1182/blood.2021012277
PMID:34375398
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8697531/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a8b/8703363/92606bc0a0c7/bloodBLD2021012277f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a8b/8703363/92606bc0a0c7/bloodBLD2021012277f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a8b/8703363/92606bc0a0c7/bloodBLD2021012277f1.jpg

相似文献

1
Antiplatelet drugs block platelet activation by VITT patient serum.抗血小板药物可阻断疫苗诱导的免疫性血小板减少症（VITT）患者血清所致的血小板活化。
Blood. 2021 Dec 23;138(25):2733-2740. doi: 10.1182/blood.2021012277.
2
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia.腺病毒载体新冠疫苗诱导的免疫性血栓性血小板减少症的相关认识。
Blood. 2021 Dec 2;138(22):2256-2268. doi: 10.1182/blood.2021013231.
3
VITT and Second Doses of Covid-19 Vaccine.疫苗诱导的免疫性血小板减少症（VITT）与新冠病毒疾病-19疫苗第二剂
N Engl J Med. 2022 Jan 6;386(1):95. doi: 10.1056/NEJMc2118507. Epub 2021 Dec 22.
4
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors.疫苗诱导的免疫性血栓性血小板减少症（VITT）：用布鲁顿酪氨酸激酶抑制剂靶向发病机制。
Thromb Haemost. 2021 Nov;121(11):1395-1399. doi: 10.1055/a-1481-3039. Epub 2021 May 28.
5
A Case Report of Thrombotic Thrombocytopenia After ChAdOx1 nCov-19 Vaccination and Heparin Use During Hemodialysis.在血液透析期间使用 ChAdOx1 nCov-19 疫苗和肝素后发生血栓性血小板减少症的病例报告。
J Korean Med Sci. 2022 Mar 14;37(10):e75. doi: 10.3346/jkms.2022.37.e75.
6
Decline in Pathogenic Antibodies over Time in VITT.疫苗诱导的血栓性血小板减少症（VITT）中致病性抗体随时间的下降
N Engl J Med. 2021 Nov 4;385(19):1815-1816. doi: 10.1056/NEJMc2112760. Epub 2021 Sep 8.
7
Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis.疫苗诱导的免疫性血小板减少症和血栓形成的临床特征。
N Engl J Med. 2021 Oct 28;385(18):1680-1689. doi: 10.1056/NEJMoa2109908. Epub 2021 Aug 11.
8
The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia.静脉注射免疫球蛋白在疫苗诱导的免疫性血栓性血小板减少症治疗中的应用。
Blood. 2021 Sep 16;138(11):992-996. doi: 10.1182/blood.2021012479.
9
Validation of the newly proposed Brighton Collaboration case definition for vaccine-induced immune thrombocytopenia and thrombosis.验证新提出的用于疫苗诱导的免疫性血小板减少症和血栓形成的布莱顿协作组病例定义。
Vaccine. 2024 Nov 14;42(25):126131. doi: 10.1016/j.vaccine.2024.07.032. Epub 2024 Jul 12.
10
Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein.抗血小板因子 4 抗体导致的 VITT 与 SARS-CoV-2 刺突蛋白不发生交叉反应。
Blood. 2021 Oct 7;138(14):1269-1277. doi: 10.1182/blood.2021012938.

引用本文的文献

1
Anti-PF4 mediated thrombocytopenia and thrombosis associated with acute cytomegalovirus infection displays both HIT-like and VITT-like characteristics.抗PF4介导的血小板减少症和与急性巨细胞病毒感染相关的血栓形成表现出类似肝素诱导的血小板减少症（HIT）和疫苗诱导的免疫性血小板减少症（VITT）的特征。
Br J Haematol. 2025 Jun;206(6):1737-1742. doi: 10.1111/bjh.20092. Epub 2025 Apr 29.
2
Platelet spleen tyrosine kinase is a key regulator of anti-PF4 antibody-induced immunothrombosis.血小板脾酪氨酸激酶是抗PF4抗体诱导的免疫血栓形成的关键调节因子。
Blood Adv. 2025 Apr 22;9(8):1772-1785. doi: 10.1182/bloodadvances.2024014167.
3
The Ambivalence of Post COVID-19 Vaccination Responses in Humans.

本文引用的文献

1
Prothrombotic immune thrombocytopenia after COVID-19 vaccination.接种 COVID-19 疫苗后的促血栓形成免疫性血小板减少症。
Blood. 2021 Jul 29;138(4):350-353. doi: 10.1182/blood.2021011958.
2
Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia.疫苗诱导的免疫性血栓性血小板减少症的辅助免疫球蛋白。
N Engl J Med. 2021 Aug 19;385(8):720-728. doi: 10.1056/NEJMoa2107051. Epub 2021 Jun 9.
3
Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia.抗体介导的 SARS-CoV-2 疫苗接种相关免疫性血栓性血小板减少症中的促凝血小板。
人类对 COVID-19 疫苗接种反应的矛盾心理。
Biomolecules. 2024 Oct 17;14(10):1320. doi: 10.3390/biom14101320.
4
Selective Btk inhibition by PRN1008/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice.PRN1008/PRN473 通过选择性抑制 BTK 阻断人 CLEC-2，且 PRN473 可减少小鼠静脉血栓形成。
Blood Adv. 2024 Nov 12;8(21):5557-5570. doi: 10.1182/bloodadvances.2024012713.
5
Vaccine-Induced Immune Thrombotic Thrombocytopenia: Clinicopathologic Features and New Perspectives on Anti-PF4 Antibody-Mediated Disorders.疫苗诱导的免疫性血栓性血小板减少症：抗PF4抗体介导疾病的临床病理特征及新观点
J Clin Med. 2024 Feb 9;13(4):1012. doi: 10.3390/jcm13041012.
6
Signaling network analysis reveals fostamatinib as a potential drug to control platelet hyperactivation during SARS-CoV-2 infection.信号转导网络分析表明，福他替尼可能是一种控制 SARS-CoV-2 感染期间血小板过度激活的潜在药物。
Front Immunol. 2023 Dec 21;14:1285345. doi: 10.3389/fimmu.2023.1285345. eCollection 2023.
7
PF4 activates the c-Mpl-Jak2 pathway in platelets.PF4 在血小板中激活 c-Mpl-Jak2 途径。
Blood. 2024 Jan 4;143(1):64-69. doi: 10.1182/blood.2023020872.
8
Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonists.二价纳米抗体与血小板 CLEC-2 结合可作为激动剂或拮抗剂。
Commun Biol. 2023 Apr 7;6(1):376. doi: 10.1038/s42003-023-04766-6.
9
Blood Coagulation and Beyond: Position Paper from the Fourth Maastricht Consensus Conference on Thrombosis.血液凝固与超越：第四届马斯特里赫特血栓形成共识会议立场文件。
Thromb Haemost. 2023 Aug;123(8):808-839. doi: 10.1055/a-2052-9175. Epub 2023 Mar 13.
10
Platelet in thrombo-inflammation: Unraveling new therapeutic targets.血小板在血栓炎症中的作用：揭示新的治疗靶点。
Front Immunol. 2022 Nov 14;13:1039843. doi: 10.3389/fimmu.2022.1039843. eCollection 2022.
Haematologica. 2021 Aug 1;106(8):2170-2179. doi: 10.3324/haematol.2021.279000.
4
Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib.用 fostamatinib 长期治疗免疫性血小板减少症期间的血栓形成风险评估。
Ther Adv Hematol. 2021 Apr 30;12:20406207211010875. doi: 10.1177/20406207211010875. eCollection 2021.
5
Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2.接种 ChAdOx1 nCoV-19 和 BNT162b2 疫苗后抗 PF4/多阴离子抗体检测阳性的频率。
Blood. 2021 Jul 29;138(4):299-303. doi: 10.1182/blood.2021012217.
6
Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study.丹麦和挪威接种牛津-阿斯利康 ChAdOx1-S 后动脉事件、静脉血栓栓塞、血小板减少和出血：基于人群的队列研究。
BMJ. 2021 May 5;373:n1114. doi: 10.1136/bmj.n1114.
7
Is complement the culprit behind COVID-19 vaccine-related adverse reactions?补体是新冠疫苗相关不良反应的罪魁祸首吗？
J Clin Invest. 2021 Jun 1;131(11). doi: 10.1172/JCI151092.
8
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.接种 ChAdOx1 nCov-19 疫苗后发生血栓性血小板减少症。
N Engl J Med. 2021 Jun 3;384(22):2092-2101. doi: 10.1056/NEJMoa2104840. Epub 2021 Apr 9.
9
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.ChAdOx1新冠疫苗接种后的血栓形成和血小板减少症
N Engl J Med. 2021 Jun 3;384(22):2124-2130. doi: 10.1056/NEJMoa2104882. Epub 2021 Apr 9.
10
Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia.在疑似肝素诱导血小板减少症的危重症 COVID-19 患者中鉴定出血小板激活免疫复合物。
J Thromb Haemost. 2021 May;19(5):1342-1347. doi: 10.1111/jth.15283. Epub 2021 Mar 14.